We provide the latest news
from the world of economics and finance
(RTTNews) - Pasithea Therapeutics Corp. (KTTA) Tuesday announced that FDA has accepted its Investigational New Drug Application or IND clearance to evaluate PAS-004 in patients with MAPK pathway-driven advanced solid tumors.
In the pre-market session, shares are gaining more than 6 percent on the Nasdaq.
Pasithea expects to dose the first patient in the first quarter of 2024.
PAS-004 is a macrocyclic MEK 1/2 inhibitor. The study targets patients with documented RAS, RAF or NF1 mutation or patients who have failed BRAF/MEK inhibition.
PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials and is expected to be an oral, once-day or less frequent dose.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.